Orchid Pharma Secures Full Rights to EXBLIFEP

  Published 8 months ago

Orchid Pharma has acquired 100% global rights to Enmetazobactam, marking a major strategic and national milestone.

  • French court approved Orchid's bid to acquire Allecra’s IP, trademarks, and global rights for EXBLIFEP (Orblicef in India).
  • This acquisition repatriates India’s first novel antibiotic molecule entirely back to India under Orchid Pharma’s ownership.
  • Orchid aims global expansion with consolidated rights, boosting brand value and financial growth in over 40 export markets.

You might like these

Malaysia Extends Biocon Biologics Insulin Contract

Concord Wins 18‑Month Kavach Rail Safety Order

Strides, Kenox Partner for Nasal Sprays

RBI Rate Cut Fuels Indian Market Rally

Biocon Wins FDA Nod for Kirsty

GAIL India's SAP S/4HANA Cloud Launch: First Maharatna PSU

RateGain and Oracle release UNO Manager

News that matters the most ⚡